ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma

Documenti analoghi

• Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma
  di: Taylor, K, et al.
  Pubblicazione: (2014)
• Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma
  di: Taylor, K, et al.
  Pubblicazione: (2014)
• Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma.
  di: Taylor, K, et al.
  Pubblicazione: (2014)
• Targeting ALK2: an open science approach to developing therapeutics for the treatment of diffuse intrinsic pontine glioma
  di: Ensan, D, et al.
  Pubblicazione: (2020)
• Leveraging an open science drug discovery model to develop CNS penetrant ALK2 inhibitors for the treatment of diffuse intrinsic pontine glioma
  di: Smil, D, et al.
  Pubblicazione: (2020)